08:46 AM EDT, 08/21/2025 (MT Newswires) -- Protagenic Therapeutics ( PTIX ) said Thursday it has completed the first patient dosing in the multiple-dose portion of its ongoing phase 1 trial of PT00114, an investigational therapy based on a brain hormone that regulates stress and emotional balance.

The company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.

Meanwhile, the company said that phase 2 studies are planned for Q1 2026.

Shares of Protagenic rose more than 74% in recent premarket activity Thursday.

Price: 3.98, Change: +1.70, Percent Change: +74.56